Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idalopirdine in mild-moderate Alzheimer's disease
NCT02006654Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Started Mar 2014; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02006654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006654.